ONE-WAYDated event · through FY2021
End of the Joint Development and Marketing License Agreement for TREAKISYM with SymBio Pharmaceuticals Limited
A matter concerning the exclusive license agreement with SymBio Pharmaceuticals Limited for the joint development and marketing of TREAKISYM in Japan, which ended in December 2020. It concerns the end of the agreement for a specific product, business partner, and joint development and marketing in Japan.
Companies2How many companies write about this.
Threads2One company can carry more than one thread here.
PeriodFY2021-Q3 →Last written FY2021
Directionhurts0 helps · 2 hurts · 0 flat